Caitong International Asset Management’s bioAffinity Technologies BIAF Stock Holding History

Caitong International Asset Management’s Portfolio BIAF Stock Details BIAF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4	Buy	+1	New	+$2	﹤0.01%	2311

Other funds holding BIAF

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JSSH

J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

AAS

Ameritas Advisory Services Lincoln, Nebraska $2.58B AUM 18.84% 1-Year Est. Return

Caitong International Asset Management's BIAF Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in bioAffinity Technologies (BIAF) in Q1 2026: 1 share worth $4. The stake represents ﹤0.01% of the portfolio and ranks #2311 among its holdings.

14 funds tracked by Wall St. Rank hold BIAF as of Q1 2026.

Caitong International Asset Management held 1 share of bioAffinity Technologies worth $4 as of Q1 2026.
bioAffinity Technologies was a new Caitong International Asset Management position in Q1 2026.
bioAffinity Technologies made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2311 holding.
14 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.